We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+2.91%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.76B
AUM Growth
-$153M
Cap. Flow
-$27.1M
Cap. Flow %
-1.54%
Top 10 Hldgs %
72.57%
Holding
43
New
2
Increased
20
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$31.7M
2
EHTH icon
eHealth
EHTH
+$30.1M
3
BIIB icon
Biogen
BIIB
+$29.4M
4
FOLD
Amicus Therapeutics
FOLD
+$29.3M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$14.6M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$104M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$41.5M
3
UTHR icon
United Therapeutics
UTHR
+$16.4M
4
INSM icon
Insmed
INSM
+$10.8M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.1%
2 Financials 4.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
26
Syndax Pharmaceuticals
SNDX
$1.77B
$5.91M 0.34%
264,200
– –
DNTH icon
27
Dianthus Therapeutics
DNTH
$6.29B
$5.12M 0.29%
27,019
+325
+1% +$54.7K
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$4.19M 0.24%
214,700
– –
TVTX icon
29
Travere Therapeutics
TVTX
$5.86B
$4.15M 0.24%
166,069
+8,169
+5% +$226K
KZR
30
DELISTED
Kezar Life Sciences
KZR
$3.91M 0.22%
65,620
+10,799
+20% +$631K
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$2.88M 0.16%
123,686
– –
RIGL icon
32
Rigel Pharmaceuticals
RIGL
$782M
$2.23M 0.13%
65,240
-34,576
-35% -$1.37M
ALIM
33
DELISTED
Alimera Sciences
ALIM
$1.93M 0.11%
200,919
– –
ALDX icon
34
Aldeyra Therapeutics
ALDX
$91.7M
$1.91M 0.11%
160,800
– –
TCMD icon
35
Tactile Systems Technology
TCMD
$555M
$1.48M 0.08%
27,100
– –
ATNX
36
DELISTED
Athenex, Inc. Common Stock
ATNX
$1.37M 0.08%
15,910
– –
SYRS
37
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$603K 0.03%
+8,060
New +$837K
MRNS
38
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$485K 0.03%
31,330
– –
URGN icon
39
UroGen Pharma
URGN
$2.39B
$477K 0.03%
24,500
– –
VIRX
40
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$307K 0.02%
33,212
-1
-0% -$10
NERV icon
41
Minerva Neurosciences
NERV
$187M
$106K 0.01%
4,540
– –
ACGN
42
DELISTED
Aceragen Inc
ACGN
$100K 0.01%
4,537
– –
APRE icon
43
Aprea Therapeutics
APRE
$8.46M
– –
-6,439
Closed -$634K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q1 2021 Portfolio in Review

As of Q1 2021, Palo Alto Investors held 43 positions worth $1.76B, down 8% from $1.91B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Palo Alto Investors's Q1 2021 filing shows 2 new, 20 increased, 8 reduced and 1 closed positions. Its largest new stake was Gritstone bio, Inc. Common Stock: 2,298,382 shares worth $21.7M. The largest sale was STAAR Surgical, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q1 2021 buy was Gritstone bio, Inc. Common Stock: 2,298,382 shares worth $21.7M.
  • Palo Alto Investors added most to eHealth in Q1 2021, an estimated $30.1M increase.
  • Palo Alto Investors's biggest Q1 2021 reduction was STAAR Surgical, cutting an estimated $104M.
  • Palo Alto Investors fully exited Aprea Therapeutics in Q1 2021, selling an estimated $634K.
  • Palo Alto Investors's ten largest holdings make up 73% of its $1.76B portfolio in Q1 2021.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q1 2021.
  • Palo Alto Investors's portfolio value fell 8% quarter-over-quarter to $1.76B.

Based on Palo Alto Investors's 13F filing for Q1 2021, filed 17 May 2021.